Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Invested Capital: 2017-2025

Historic Invested Capital for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $120.1 million.

  • Aclaris Therapeutics' Invested Capital fell 7.72% to $120.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.1 million, marking a year-over-year decrease of 7.72%. This contributed to the annual value of $155.6 million for FY2024, which is 1.03% down from last year.
  • Aclaris Therapeutics' Invested Capital amounted to $120.1 million in Q3 2025, which was down 8.83% from $131.7 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Invested Capital ranged from a high of $244.5 million in Q2 2021 and a low of $120.1 million during Q3 2025.
  • Moreover, its 3-year median value for Invested Capital was $144.1 million (2025), whereas its average is $148.0 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Invested Capital surged by 321.61% in 2021 and then dropped by 28.89% in 2023.
  • Aclaris Therapeutics' Invested Capital (Quarterly) stood at $197.3 million in 2021, then climbed by 0.14% to $197.6 million in 2022, then dropped by 20.46% to $157.2 million in 2023, then declined by 1.03% to $155.6 million in 2024, then fell by 7.72% to $120.1 million in 2025.
  • Its last three reported values are $120.1 million in Q3 2025, $131.7 million for Q2 2025, and $144.1 million during Q1 2025.